The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show response to HCTZ 25 mg over a 4-week period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
726
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
Unnamed facility
Investigative Centers, Germany
Mean sitting diastolic blood pressure lowering effect at baseline, and week 8.
Mean sitting systolic blood pressure (msDBP) lowering from baseline to week 8
Safety and tolerability
Proportion of patients achieving a blood pressure control target at week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.